News & Media
|Hemostemix Names Dr. Hardean E. Achneck as Vice President of Clinical Research and Operations|
|Feb 02 2015 -
Hemostemix Inc. (the “Corporation”) (TSX-V: “HEM”) announced today the appointment of Dr. Hardean E. Achneck, MD, as vice president of clinical research and operations.
“Hardean brings to Hemostemix a rare combination of scientific expertise and clinical experience,” said Dr. Elmar Burchardt, President and CEO. “His pioneering interdisciplinary research provides a strong foundation for leading our clinical trials and developing clinical trial partnerships.”
Prior to joining the Hemostemix management team, Dr. Achneck held assistant professorships in pathology and surgery at Duke University School of Medicine and in cardiovascular and metabolic disorders at Duke-National University of Singapore Graduate Medical School (Duke-NUS). At these institutions, he served as principal investigator on preclinical and clinical research studies in cardiovascular medicine and was responsible for identifying clinical research opportunities for Duke University Medical Center. He earned an MD degree from Yale University School of Medicine.
Dr. Achneck’s research and development experience includes cell therapies as well as medical combination devices that use endothelial progenitor cells (EPCs) derived from a patient’s blood. He invented a rapid point-of-care cell-seeding technology and authored more than 20 peer-reviewed publications in the field of blood-derived cell therapies.
“Hemostemix presents a unique opportunity to leverage my cell-therapy experience in an entrepreneurial setting,” said Dr. Achneck. “I look forward to advancing the clinical trials, science, and operations in collaboration with our scientific team in Israel.”
For more information, please contact email@example.com